

**SynAct Pharma AB**  
**EXPAND Study Update**



**September 13 2023**

# Forward Looking Statements

Certain information set forth in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and may include, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company’s current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.


Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

# Consistent activity seen in patients with evidence of active inflammation


- **Resomelagon treated patients with elevated CRP at baseline (> 3mg/L) exhibited consistent responsiveness over placebo at 12 weeks across all outcome measures**
  - 70.6% of resomelagon treated patients achieved an ACR20 response compared to 54.3% on placebo
  - The Health Assessment Questionnaire-Disability Index (HAQ-DI), a component of the ACR scoring system improved by almost 3x the minimum clinical important difference (MCID)
  - Improvements were seen in the CDAI and DAS28 scoring systems that mirrored those seen with ACR20
- **These patients have elevated CRP, a blood marker of systemic inflammation**
  - Increased responsiveness in this population supports the potential of inflammation resolution
- **Identifying this population is important in helping us understand the EXPAND study, prepare for the release of the RESOLVE 2a study (~70% of RESOLVE 2a patients have CRP>3mg/L) as well as for future clinical trial design like RESOLVE P2b**

# The EXPAND study – ACR20

## All pts




## Baseline hsCRP > 3




# The EXPAND study - ACR Scores following 12 weeks treatment

## All pts




## Baseline hsCRP > 3




# The EXPAND study – Changes in Health Assessment Questionnaire (HAQ) -

## All pts




## Baseline hsCRP > 3




# % of patients reaching minimum clinical important difference (MCID) in HAQ score



## All pts



## Baseline hsCRP > 3




# The EXPAND study – Changes in CDAI






# The EXPAND study – Changes in DAS28

## All pts




## Baseline hsCRP > 3



# Consistent activity seen in patients with evidence of active inflammation

- **Resomelagon treated patients with elevated CRP at baseline (> 3mg/L) exhibited consistent responsiveness over placebo at 12 weeks across all outcome measures**
  - 70.6% of resomelagon treated patients achieved an ACR20 response compared to 54.3% on placebo
  - The Health Assessment Questionnaire-Disability Index (HAQ-DI), a component of the ACR scoring system improved by almost 3x the minimum clinical important difference (MCID)
  - Improvements were seen in the CDAI and DAS28 scoring systems that mirrored those seen with ACR20
- **These patients have elevated CRP, a blood marker of systemic inflammation**
  - Increased responsiveness in this population supports the potential of inflammation resolution
- **Identifying this population is important in helping us understand the EXPAND study, prepare for the release of the RESOLVE 2a study (~70% of RESOLVE 2a patients have CRP>3mg/L) as well as for future clinical trial design like RESOLVE P2b**

# Upcoming news flow



- ✓ September: Topline results from Expand
- ✓ Sub analysis from Expand and secondary variables

October: Topline results from Part A Resolve

More results from Expand

More results from Part A Resolve

Initiation of Resolve Part B

Initiation of Phase I TXP-11

More pipeline updates